Most notably, we did not test ROR1 expression in hematologic tumors; this is especially relevant in lymphoid cancers treated with zilovertamab vedotin, an antibody–drug conjugate targeting ROR1 that includes monomethyl auristatin E, a microtubule cytotoxin payload that demonstrated antitumor activity [36]. Here, ROR1 is linked to lymphoma.